What is Day Zero Diagnostics?
Based in Boston and founded in 2016 by a cohort of clinicians and scientists from Harvard University and Massachusetts General Hospital, Day Zero Diagnostics is pioneering a paradigm shift in clinical microbiology. By integrating whole-genome sequencing with sophisticated machine learning algorithms, the company bypasses traditional culture-based methods to rapidly identify pathogens and their specific antibiotic resistance profiles. This technological leap not only accelerates patient treatment timelines but also provides healthcare systems with the big data infrastructure necessary to manage and contain hospital-acquired infection outbreaks effectively. The firm has garnered significant industry recognition from organizations such as CARB-X and MassChallenge HealthTech, validating its role as a transformative force in modern medicine.
How much funding has Day Zero Diagnostics raised?
Day Zero Diagnostics has raised a total of $55.3M across 6 funding rounds:
Angel/Seed
$3M
Series A
$8.6M
Corporate Investment
$6.2M
Debt
$467K
Unspecified
$21M
Other Financing Round
$16M
Angel/Seed (2017): $3M with participation from Golden Seeds and Sands Capital
Series A (2019): $8.6M, investors not publicly disclosed
Corporate Investment (2020): $6.2M supported by Carb-X
Debt (2021): $467K featuring PPP
Unspecified (2022): $21M backed by Golden Seeds, Sands Capital, Triventures, Panacea Ventures, Hongkou Capital, and BD
Other Financing Round (2023): $16M, investors not publicly disclosed
Key Investors in Day Zero Diagnostics
Carb-X
CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and life-saving products to combat dangerous drug-resistant bacteria.
Golden Seeds
A venture capital firm specializing in start-up, early stage, and growth capital investments with a broad geographic footprint across the United States.
Sands Capital
An established investment management firm that manages equity mutual funds and invests in public equity markets with a focus on long-term growth.
What's next for Day Zero Diagnostics?
With the support of its latest financing, Day Zero Diagnostics is well-positioned to scale its operations and accelerate the commercialization of its diagnostic suite. The company is expected to focus on expanding its clinical validation studies and deepening its integration into hospital laboratory workflows. As the firm transitions into a more mature enterprise phase, the strategic deployment of these funds will likely prioritize the refinement of its machine learning models and the expansion of its genomic database, ensuring that its diagnostic tools remain at the forefront of the fight against drug-resistant bacteria. Continued collaboration with global medical technology partners will be essential for the widespread adoption of its culture-free diagnostic solutions.
See full Day Zero Diagnostics company page
